Antidepressant and antipsychotic use in an Italian pediatric population

BMC Pediatrics

Volumn 11, Issue , 2011, Pages

  Clavenna, Antonio ^a   Andretta, Margherita ^b   Pilati, Paola ^b   Dusi, Maurizio ^c   Gangemi, Michele ^d   Gattoni, Maria B ^d   Lombardo, Giuseppe ^d   Zoccante, Leonardo ^e   Mezzalira, Luigi ^b   Bonati, Maurizio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b ULSS 20   (Italy)

^c Ospedale Villa Santa Giuliana   (Italy)

^d Policlinico GB Rossi ^*  (Italy)

^e Policlinico GB Rossi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOTIAPINE; ESCITALOPRAM; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; SERTRALINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL EVALUATION; DATA BASE; DIAGNOSTIC PROCEDURE; DROWSINESS; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; INCIDENCE; INCREASED APPETITE; INFORMATION PROCESSING; IRRITABILITY; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MIXED ANXIETY AND DEPRESSION; OUTCOME ASSESSMENT; PHYSICIAN; PRESCRIPTION; PREVALENCE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; ANXIETY; CHILD; DEPRESSION; MENTAL DISEASE; MENTAL HEALTH SERVICE; STATISTICS;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DEPRESSION; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INCIDENCE; ITALY; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; PREVALENCE;

EID: 79956220307     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-11-40     Document Type: Article

References (36)

1. Raz A. Perspectives on the efficacy of antidepressants for child and adolescent depression. PloS Med 2006, 3:e9. 1315362, 16354104.
2. Wohlfarth T, Kalverdijk L, Rademarker C, Schothorst P, Minderaa R, Gispen-de Wied C. Psychopharmacology for children: from off label use to registration. Eur Neuropsychopharmacol 2009, 19:603-608. 10.1016/j.euroneuro.2009.04.007, 19428221.
3. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006, 63:332-339. 10.1001/archpsyc.63.3.332, 16520440.
4. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009, 339:b2880. 10.1136/bmj.b2880, 2725270, 19671933.
5. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297:1683-1696. 10.1001/jama.297.15.1683, 17440145.
6. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002, CD002317.
7. Usala T, Clavenna A, Zuddas A, Bonati M. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: A systematic review and meta-analysis. Eur Neuropsychopharmacol 2008, 18:62-73. 10.1016/j.euroneuro.2007.06.001, 17662579.
8. Cohen D, Deniau E, Maturana A, Tanguy ML, Bodeau N, Labelle R, Breton JJ, Guile JM. Are child and adolescent responses to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials. PLoS One 2008, 3:e2632. 10.1371/journal.pone.0002632, 2435626, 18612460.
9. Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol (in press) doi.org/10.1016/j.euroneuro.2010.07.002.
10. Kapetanovic S, Simpson GM. Review of antipsychotics in children and adolescents. Expert Opin Pharmacother 2006, 7:1871-1885. 10.1517/14656566.7.14.1871, 17020414.
11. Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews 2007, (1). Art. No.: CD005040. DOI: 10.1002/14651858.CD005040.pub2.
12. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 2008, 69:9-14. 10.4088/JCP.0308e09, 18533763.
13. Kaiser J. Ethics. Private money, public disclosure. Science 2009, 325(5936):28-30. 10.1126/science.325_28, 19574366.
14. Bonati M, Clavenna A. The epidemiology of psychotropic drug use in children and adolescents. Int Rev Psychiatry 2005, 17:181-188. 10.1080/09540260500093768, 16194789.
15. Zito JM, Safer DJ, de Jong-van den Berg LT, Janhsen K, Fegert JM, Gardner JF, Glaeske G, Valluri SC. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008, 2:26. 10.1186/1753-2000-2-26, 2569908, 18817536.
16. Acquaviva E, Legleye S, Auleley GR, Deligne J, Carel D, Falissard B B. Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry 2009, 17:72.
17. Zoëga H, Baldursson G, Hrafnkelsson B, Almarsdóttir AB, Valdimarsdóttir U, Halldórsson M. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 2009, 19:757-764. 10.1089/cap.2009.0003, 20035594.
18. Clavenna A, Rossi E, De Rosa M, Bonati M. Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr 2007, 166:339-347. 10.1007/s00431-006-0244-7, 17028883.
19. Clavenna A, Berti A, Gualandi L, Rossi E, De Rosa M, Bonati M. Drug utilisation profile in the Italian paediatric population. Eur J Pediatr 2009, 168:173-180. 10.1007/s00431-008-0725-y, 18446366.
20. Nardocci F. The birth of child and adolescent neuropsychiatry: from rehabilitation and social inclusion of the mentally handicapped, to the care of mental health during development. Ann Ist Super Sanità 2009, 45:33-38.
21. Percudani M, Barbui C, Fortino I, Petrovich L. Worrying patterns of out-patient psychotropic drug prescribing in children and adolescents. Psychother Psychosom 2005, 74:189-190. 10.1159/000084005, 15832071.
22. Clavenna A, Bonati M. Antidepressant prescriptions in paediatric outpatients in Europe. Paediat Perinat Drug Ther 2007, 8:103-108.
23. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009, 66:848-856. 10.1001/archgenpsychiatry.2009.81, 19652124.
24. Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008, 121:1002-1009. 10.1542/peds.2007-2008, 18450906.
25. European Medicines Agency European Medicines Agency finalises review of antidepressants in children and adolescents. (accessed 31 March 2011), European Medicines Agency., http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/12/news_detail_000882.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1
26. Food and Drug Administration Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications. (accessed 31 March 2011), Food and Drug Administration., http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm
27. Gruppo di lavoro OSMED L'uso dei farmaci in Italia. Rapporto nazionale anno 2008 2009, Roma: Il Pensiero Scientifico Editore, Gruppo di lavoro OSMED.
28. Emslie, GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 2009, 48:721-729. 10.1097/CHI.0b013e3181a2b304, 19465881.
29. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006, 45:280-288. 10.1097/01.chi.0000192250.38400.9e, 16540812.
30. National Institute of Clinical Excellence Depression in children and young people. Identification and management in primary, community and secondary care. Clinical Guideline 28. (accessed 31 March 2011), National Institute of Clinical Excellence., http://www.nice.org.uk/CG028
31. Frigerio A, Rucci P, Goodman R, Ammaniti M, Carlet O, Cavolina P, De Girolamo G, Lenti C, Lucarelli L, Mani E, Martinuzzi A, Micali N, Milone A, Morosini P, Muratori F, Nardocci F, Pastore V, Polidori G, Tullini A, Vanzin L, Villa L, Walder M, Zuddas A, Molteni M. Prevalence and correlates of mental disorders among adolescents in Italy: The PrISMA study. Eur Child Adolesc Psychiatry 2009, 18:217-226. 10.1007/s00787-008-0720-x, 19165539.
32. Didoni A, Costantino MA, Panei P, Clavenna A, Bonati M. Pharmacological treatment ADHD children of Lombardy Region (Italy) [abstract]. 12th ESDPPP Congress June 17th to 20th.
33. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008, 69(Suppl 4):26-36.
34. Jerrell JM, Hwang TL, Livingston TS. Neurological adverse events associated with antipsychotic treatment in children and adolescents. J Child Neurol 2008, 23:1392-1399. 10.1177/0883073808319070, 18772491.
35. Birmaher B, Axelson D, Goldstein B, Monk K, Kalas C, Obreja M, Hickey MB, Iyengar S, Brent D, Shamseddeen W, Diler R, Kupfer D. Psychiatric disorders in preschool offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring Study (BIOS). Am J Psychiatry 2010, 167:321-330. 10.1176/appi.ajp.2009.09070977, 2868596, 20080982.
36. Verhulst FC, van der Ende J. Factors associated with child mental health service use in the community. J Am Acad Child Adolesc Psychiatry 1997, 36:901-909. 10.1097/00004583-199707000-00011, 9204667.